Lenzilumab & Evusheld Make It Onto EU List Of ‘Most Promising’ COVID-19 Treatments
EMA Begins Rolling Review Of Molnupiravir
Executive Summary
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
You may also be interested in...
Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.
Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.
EMA Considers EUA-Style Fast Track Decision For Molnupiravir
The European Medicines Agency is considering making a rapid recommendation on MSD’s molnupiravir in order to speed access to the potential ‘game changer’ COVID-19 pill.